First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Janku F, Beom SH, Moon YW, Kim TW, Shin YG, Yim DS, Kim GM, Kim HS, Kim SY, Cheong JH, Lee YW, Geiger B, Yoo S, Thurston A, Welsch D, Rudoltz MS, Rha SY.
Janku F, et al. Among authors: rha sy.
Invest New Drugs. 2022 Oct;40(5):1001-1010. doi: 10.1007/s10637-022-01277-9. Epub 2022 Jul 8.
Invest New Drugs. 2022.
PMID: 35802288
Free PMC article.
Clinical Trial.